siRNA-mediated antitumorigenesis for drug target validation and therapeutics

Current Opinion in Molecular Therapeutics

Volumn 5, Issue 3, 2003, Pages 225-234

  Lu, Patrick Y ^a   Xie, Frank Y ^a   Woodle, Martin C ^a  

^a Intradigm Corporation   (United States)

Author keywords

Drug target; siRNA; Target validation; Therapeutics; Tumor inhibition; Tumorigenesis

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; LIPOFECTAMINE; MESSENGER RNA; PROTEIN KINASE C; RETROVIRUS VECTOR; RNA;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; BIOMEDICINE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER RESEARCH; CANCER THERAPY; CARCINOGENESIS; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; ELECTROPORATION; GENE DELIVERY SYSTEM; GENE TARGETING; GENOME ANALYSIS; HUMAN; HUMAN CELL; NONHUMAN; REVIEW; TARGET CELL; TUMOR MODEL; VALIDATION PROCESS; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CELL CYCLE; GENE SILENCING; GENE TARGETING; GENE THERAPY; GENE TRANSFER TECHNIQUES; GROWTH SUBSTANCES; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN KINASES; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA; UNIDENTIFIED RETROVIRUS;

EID: 0141613693     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Hannon GJ: RNA interference. Nature (2002) 418(6894):244-251.
2. McManus MT, Sharp PA: Gene silencing in mammals by small interfering RNAs. Nat Rev Genet (2002) 3(10):737-747.
3. Couzin J: Breakthrough of the year: Small RNAs make big splash. Science (2002) 298(5602):2296-2297.
4. Ahn J, Urist M, Prives C: Questioning the role of Chk2 in the p53 DNA damage response. J Biol Chem (2003) 278(23):20480-20489.
5. Ohtsuka T, Ryu H, Minamishima YA, Ryo A, Lee SW: Modulation of p53 and p73 levels by cyclin G: Implication of a negative feedback regulation. Oncogene (2003) 22(11):1678-1687.
6. Martinez LA, Naguibneva I, Lehrmann H, Vervisch A, Tchenio T, Lozano G, Harel-Bellan A: Synthetic small inhibiting RNAs: Efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc Natl Acad Sci USA (2002) 99(23):14849-14854.
7. Zou X, Ray D, Aziyu A, Christov K, Boiko AD, Gudkov AV, Kiyokawa H: Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence. Genes Dev (2002) 16(22):2923-2934.
8. 1/S Cell cycle arrest in response to DNA damage. J Biol Chem (2003) 278(4):2101-2105.
9. Kartasheva NN, Contente A, Lenz-Stoppler C, Roth J, Dobbelstein M: p53 Induces the expression of its antagonist p73 δN, establishing an autoregulatory feedback loop. Oncogene (2002) 21(31):4715-4727.
10. Jiang M, Milner J: Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. Oncogene (2002) 21(39):6041-6048.
11. Jiang M, Milner J: Bcl-2 constitutively suppresses p53-dependent apoptosis in colorectal cancer cells. Genes Dev (2003) 17(7):832-837.
12. Nikolaev AY, Li M, Puskas N, Qin J, Gu W: Parc: A cytoplasmic anchor for p53. Cell (2003) 112(1):29-40.
13. Wang B, Matsuoka S, Carpenter PB, Elledge SJ: 53BP1, a mediator of the DNA damage checkpoint. Science (2002) 298(5597):1435-1438.
14. Shu X, Wu W, Mosteller RD, Broek D: Sphingosine kinase mediates vascular endothelial growth factor-induced activation of ras and mitogen-activated protein kinases. Mol Cell Biol (2002) 22(22):7758-7768.
15. 165b expression by RNA interference technique. J Physiol (Lond) (2003):547.
16. Lu PY, Xie FY, Tang QQ, Xu J, Liu YJ, Zhou Q, Scaria P, Li L, Woodle MC: Tumor inhibition by siRNA-mediated anti-angiogenesis in xonografted tumor models. Molecular Targets for Cancer Therapy Banff, Alberta, Canada (2003).
17. Nagy P, Arndt-Jovin DJ, Jovin TM: Small interfering RNAs suppress the expression of endogenous and GFP-fused epidermal growth factor receptor (erbB1) and induce apoptosis in erbB1-overexpressing cells. Exp Cell Res (2003) 285(1):39-49.
18. Siegmund D, Hadwiger P, Pfizenmaier K, Vomlocher HP, Wajant H. Selective inhibition of FLICE-like inhibitory protein expression with small interfering RNA oligonucleotides is sufficient to sensitize tumor cells for TRAIL-induced apoptosis. Mol Med (2002) 8(11):725-732.
19. McManus MT, Haines BB, Dillon CP, Whitehurst CE, van Parijs L, Chen J, Sharp PA: Small interfering RNA-mediated gene silencing in T-lymphocytes. J Immunol (2002) 169(10):5754-5760.
20. Irie N, Sakai N, Ueyama T, Kajimoto T, Shirai Y, Saito N: Subtype- and species-specific knockdown of PKC using short interfering RNA. Biochem Biophys Res Commun (2002) 298(5):738-743.
21. Czauderna F, Fechtner M, Aygun H, Arnold W, Klippel A, Giese K, Kaufmann J: Functional studies of the PI(3)-kinase signalling pathway employing synthetic and expressed siRNA. Nucleic Acids Res (2003) 31(2):670-682.
22. Collis SJ, Swartz MJ, Nelson WG, DeWeese TL: Enhanced radiation and chemotherapy-mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors. Cancer Res (2003) 63(7):1550-1554.
23. Spankuch-Schmitt B, Bereiter-Hahn J, Kaufmann M, Strebhardt K: Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Inst (2002) 94(24):1863-1877.
24. Boehm M, Yoshimoto T, Crook MF, Nallamshetty S, True A, Nabel GJ, Nabel EG: A growth factor-dependent nuclear kinase phosphorylates p27(kip1) and regulates cell cycle progression. EMBO J (2002) 21(13):3390-3401.
25. Dammermann A, Merdes A: Assembly of centrosomal proteins and microtubule organization depends an PCM-1. J Cell Biol (2002) 159(2):255-266.
26. Zhang D, Li F, Weidner D, Mnjoyan ZH, Fujise K: Physical and functional interaction between myeloid cell leukemia 1 protein (MCL1) and fortilin. the potential role of MCL1 as a fortilin chaperone. J Biol Chem (2002) 277(40):37430-37438.
27. Porter LA, Dellinger RW, Tynan JA, Barnes EA, Kong M, Lenormand JL, Donoghue DJ: Human Speedy: A novel cell cycle regulator that enhances proliferation through activation of Cdk2. J Cell Biol (2002) 157(3):357-366.
28. Mollinari C, Kleman JP, Jiang W, Schoehn G, Hunter T, Margolis RL: PRC1 is a microtubule binding and bundling protein essential to maintain the mitotic spindle midzone. J Cell Biol (2002) 157(7):1175-1186.
29. Verma UN, Surabhi RM, Schmaltieg A, Becerra C, Gaynor RB: Small interfering RNAs directed against β-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res (2003) 9(4):1291-1300.
30. Stoecklin G, Colombi M, Raineri I, Leuenberger S, Mallaun M, Schmidlin M, Gross B, Lu M, Kitamura T, Moroni C: Functional cloning of BRF1, a regulator of ARE-dependent mRNA turnover. EMBO J (2002) 21(17):4709-4718.
31. Rajendran RR, Nye AC, Frasor J, Balsara RD, Martini PG, Katzenellenbogen BS: Regulation of nuclear receptor transcriptional activity by a novel DEAD box RNA helicase (dp97). J Biol Chem (2003) 278(7):4628-4638.
32. Scherr M, Battmer K, Winkler T, Heidenreich O, Ganser A, Eder M: Specific inhibition of bcr-abl gene expression by small interfering RNA. Blood (2003) 101(4):1566-1569.
33. Stewart GS, Wang B, Bignell CR, Taylor AM, Elledge SJ: MDC1 is a mediator of the mammalian DNA damage checkpoint. Nature (2003) 421(6926):961-966.
34. Tuynder M, Susini L, Prieur S, Besse S, Fiucci G, Amson R, Telerman A: Biological models and genes of tumor reversion: Cellular reprogramming through tpt1/TCTP and SIAH-1. Proc Natl Acad Sci USA (2002) 99(23):14976-14981.
35. McCaffrey AP, Meuse L, Pham TT, Conklin DS, Hannon GJ, Kay MA: RNA interference in adult mice. Nature (2002) 418(6893):38-39.
36. Lewis DL, Hagstrom JE, Loomis AG, Wolff JA, Herweijer H: Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat Genet (2002) 32(1):107-108.
37. Xu J, Xie FY, Tang QQ, Scaria P, Liu YJ, Zhou Q, Tang TB, Woodle MC, Lu PY: Target identification and validation using RNAi in xenograft tumor models. Drug Target Validation: Gene Suppression Tahoe City, CA, USA (2003).
38. Sorensen DR, Leirdal M, Sioud M: Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol (2003) 327(4):761-766.
39. Brummelkamp TR, Bernards R, Agami R: A system for stable expression of short interfering RNAs in mammalian cells. Science (2002) 296(5567):550-553.
40. Brummelkamp TR, Bernards R, Agami R: Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell (2002) 2(3):243-247.
41. Yu JY, DeRuiter SL, Turner DL: RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proc Natl Acad Sci USA (2002) 99(9):6047-6052.
42. Xia H, Mao Q, Paulson HL, Davidson BL: siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol (2002) 20(10):1006-1010.
43. Devroe E, Silver PA: Retrovirus-delivered siRNA. BMC Biotechnol (2002) 2(1):15.
44. Tiscornia G, Singer O, Ikawa M, Verma IM: A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. Proc Natl Acad Sci USA (2003) 100(4):1844-1848.
45. Abbas-Terki T, Blanco-Bose W, Deglon N, Pralong W, Aebischer P: Lentiviral-mediated RNA interference. Hum Gene Ther (2002) 13(18):2197-2201.
46. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA et al: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 419(6907):624-629.
47. Bohula EA, Salisbury AJ, Sohail M, Playford MP, Riedemann J, Southern EM, Macaulay VM: The efficacy of small interfering RNAs targeted to the type 1 insulin-like growth factor receptor (IGF1R) is influenced by secondary structure in the IGF1R transcript. J Biol Chem (2003) 278(18):15991-15997.
48. Vickers TA, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF: Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis. J Biol Chem (2003) 278(9):7108-7118.